home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

THE CONTROLLING CANCER SUMMIT 2016: 17TH – 19TH MAY 2016

 
  May 20, 2015  
     
 


Euroscicon, London, UK
17TH – 19TH MAY 2016


The annual Controlling Cancer Summit in an international academic event with plenty of opportunity  for networking and debate. In an informal setting, this meeting will bring you up to date with current research and thinking regarding screening, prevention and treatment in  this ever-growing field.  Presenting at this event, we will have a variety of clinicians, academics and members of the pharmaceutical industry; we encourage presentations from  the wide spectrum of cancer research, development and healthcare professionals.  

 
This innovative and stimulating event will is aimed at those working in research and development of drugs, industry partners, academia, biotechnology, diagnostics, clinicians and postgraduate students.

Hashtag: #cancer2016

This event has an open abstract session.  
Abstracts can be submitted on any subject related to cancer.
The Deadline for abstract submissions for oral presentation is February 10th 2016
Abstracts for poster presentation only can be submitted up to two weeks before the event
You can download the instructions for authors at 

www.euroscicon.com/ABSTRACTSUBMISSIONS.pdf


This event has CPD accreditation

 
 
Organized by: Euroscicon
Invited Speakers: Please see our website for an up-to-date agenda.
 
Deadline for Abstracts: The Deadline for abstract submissions for oral presentation is February 10th 2016
 
Registration: To register please click here
E-mail: enquiries@euroscicon.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.